STOCK TITAN

Legend Biotech Corp - LEGN STOCK NEWS

Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.

Overview of Legend Biotech Corp

Legend Biotech Corp (NASDAQ: LEGN) is a clinical-stage biopharmaceutical company dedicated to harnessing cutting-edge cell therapy and CAR-T immunotherapy technologies to revolutionize the treatment of cancer, particularly multiple myeloma and other oncology indications. With a robust pipeline of chimeric antigen receptor (CAR) product candidates, the company leverages advanced scientific research and decades of expertise in molecular biology and immunology to address previously unmet medical needs in oncology.

Core Business and Strategic Focus

The core business of Legend Biotech revolves around the discovery, development, and clinical application of next-generation cell therapies. The company utilizes its proprietary platforms to develop CAR-T cell therapies that are designed to target and eliminate malignant cells in patients with liquid and solid tumors. By focusing on cancers that have long been considered incurable, such as multiple myeloma, Legend Biotech aims to improve treatment outcomes and extend patient survival. The company generates revenue through strategic licensing and collaboration agreements, partnering with established industry players to expand the reach of its innovative therapies.

Research, Development, and Innovation

Legend Biotech is recognized for its commitment to research and development. The company operates multiple R&D sites around the globe, ensuring a diverse and comprehensive approach to clinical research. Its teams of immunologists and molecular biologists work collaboratively to fine-tune CAR-T cell constructs and other cell-based therapies. This rigorous R&D approach has resulted in a strong pipeline of product candidates that undergo extensive clinical trials, with several therapies demonstrating promising efficacy in early and advanced stages of clinical evaluation.

Technology Platform and Pipeline

The company’s technology platform is built on the complex science of cellular engineering, enabling the development of both autologous and allogeneic cell therapies. These therapies often involve the genetic modification of a patient’s own immune cells to enhance their ability to recognize and kill cancer cells. A key product in its portfolio is a BCMA-targeted CAR-T cell therapy, which has shown significant clinical potential in treating relapsed or refractory multiple myeloma. This approach not only refines the patient’s immune response but also opens avenues for additional therapeutic applications across various oncologic disorders.

Market Position and Collaborative Strength

Within the competitive landscape of biopharmaceutical innovation, Legend Biotech positions itself as a vital contributor to the next generation of cancer treatment. The company’s involvement in high-profile clinical trials and its collaboration with major industry partners underscore its authoritative presence in the field. Its licensing and collaboration agreements with renowned organizations further reinforce its scientific credibility and operational robustness, positioning the company as an important player in global oncology research and treatment development.

Pipeline and Clinical Impact

Legend Biotech’s pipeline reflects its dedication to transforming cancer treatment paradigms. The company’s clinical trials have evaluated the safety and efficacy of its CAR-T therapies among diverse patient groups. These studies are designed to demonstrate not only impressive clinical responses but also enhancements in overall survival and quality of life among patients with challenging oncologic diagnoses. By rigorously testing its product candidates in multiple clinical settings, Legend Biotech contributes valuable data to the scientific community and paves the way for the broader adoption of cell therapies in routine clinical practice.

Scientific Rigor and Regulatory Engagement

Undergirding its product development is a strong commitment to scientific rigor and regulatory compliance. Legend Biotech adheres to strict quality standards in the development and manufacturing of its therapies, ensuring both efficacy and patient safety. Its active engagement with regulatory bodies worldwide reflects a proactive approach to meeting global standards, thereby enhancing the trust of both patients and healthcare providers in its therapies.

Commitment to Advancing Oncology Treatment

At its core, Legend Biotech is driven by the vision of overcoming the long-standing challenges in cancer treatment. By advancing the science of cell therapies, the company seeks to offer novel, potentially transformative treatments that redefine the standard of care in oncology. Its comprehensive approach, which integrates innovative research, deep scientific expertise, and strategic collaborations, enables Legend Biotech to contribute meaningfully to the evolving landscape of immunotherapy and personalized medicine.

Key Highlights

  • Innovative Cell Therapies: Focused on CAR-T cell therapies for addressing difficult-to-treat cancers, especially in the field of oncology.
  • Advanced R&D: Multiple research centers globally support expansive R&D efforts and clinical trials.
  • Collaborative Revenue Model: Strategic licensing and collaboration agreements enhance scientific advancement and market reach.
  • Clinical Expertise: Demonstrated capabilities in conducting rigorous clinical trials and generating actionable clinical data.
  • Regulatory Engagement: Active interactions with regulatory agencies ensure adherence to high quality and safety standards.

Conclusion

Legend Biotech Corp stands as a formidable entity in the field of biotechnology, focusing on the development of best-in-class immunotherapies. Through its innovative cell therapy platforms and robust clinical research programs, the company is committed to revolutionizing cancer treatment and improving patient outcomes in oncology. Its deep scientific expertise, combined with a strategic approach to R&D and global collaborations, solidifies its reputation as an authoritative and trustworthy source in the biopharmaceutical landscape.

Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary financial results for the year ended December 31, 2020, projecting a loss of approximately US$292.2 million to US$324.9 million, with an adjusted loss of US$202.4 million to US$234.4 million. The losses primarily stem from substantial R&D expenses totaling US$220.7 million to US$255.6 million linked to its lead product candidate, cilta-cel. Additionally, a one-time non-cash fair value loss of about US$80 million was reported due to the conversion of Series A preferred shares. As of year-end, the company held roughly US$455.7 million in cash and equivalents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has commenced the submission of a Biologics License Application (BLA) to the FDA for cilta-cel, a CAR-T therapy aimed at treating relapsed or refractory multiple myeloma. This initiative is rooted in the pivotal CARTITUDE-1 study, which demonstrated significant efficacy and safety. The collaboration with Janssen has also resulted in a $75M milestone payment due to the progress of cilta-cel. The FDA's previous Breakthrough Therapy Designation for cilta-cel underlines its potential impact in addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. CEO Ying Huang will provide updates on January 13, 2021, at 4:30 PM ET. The event will be accessible via a webcast available on their website. Legend Biotech focuses on developing novel cell therapies, particularly its lead candidate, ciltacabtagene autoleucel, targeting multiple myeloma, currently in registrational trials. The company employs over 800 staff across the globe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has been added to the NASDAQ Biotechnology Index, effective December 21, 2020. This addition is part of the annual re-ranking, where 100 biotech stocks were included, while 16 were removed. The NASDAQ Biotechnology Index tracks biotechnology and pharmaceutical securities listed on NASDAQ, calculated using a modified capitalization-weighted methodology. Legend Biotech focuses on novel cell therapies for oncology, notably its lead candidate, ciltacabtagene autoleucel, for multiple myeloma, currently in registrational clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) has received FDA clearance for its Investigational New Drug (IND) application to evaluate LB1901, an autologous CAR-T therapy targeting relapsed or refractory T-cell lymphoma (TCL). This clearance allows the company to initiate a Phase 1 clinical study in the U.S., focusing on safety, tolerability, and the recommended Phase 2 dose. TCL represents a significant unmet medical need, with PTCL and CTCL often leading to poor survival rates. CEO Ying Huang emphasized the importance of this milestone for the company’s innovation in cell therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
none
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) announced encouraging results from the Phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed or refractory multiple myeloma. With a median follow-up of 12.4 months, the overall response rate (ORR) reached 97%, with 67% achieving stringent complete response. The study included 97 patients with a history of extensive prior therapies. Safety data indicated manageable adverse events, with most being Grade 1/2. The findings suggest cilta-cel could be a transformative option for patients in need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) has appointed Dr. Patrick Casey as an independent director to its Board of Directors. Dr. Casey's extensive expertise in scientific research, particularly in pharmacology and cancer biology, is seen as a significant addition to the board. His role is expected to bolster Legend Biotech's efforts in developing innovative cell therapies, particularly its lead product candidate, ciltacabtagene autoleucel, aimed at treating multiple myeloma. The appointment reflects the company's commitment to its pipeline development strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
management
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) is set to host a virtual Key Opinion Leader (KOL) event on December 7 at 7 pm ET. This event will showcase the latest data from the CARTITUDE-1 study (NCT03548207), focusing on ciltacabtagene autoleucel (cilta-cel), a CAR-T cell therapy for relapsed or refractory multiple myeloma. Presentations will include insights from experts in hematology and oncology, including Ying Huang, CEO, and leading medical professionals. Register and access the webcast at LegendBiotechASH2020.Convene.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
-
Rhea-AI Summary

Legend Biotech Corporation (NASDAQ: LEGN) announced the appointment of Dr. Li Zhu to its Board of Directors as a Class III director. Dr. Zhu's experience includes key roles at GenScript Biotech and Clontech Laboratories, enhancing the Board's strategic capabilities. Concurrently, Dr. Fangliang Zhang resigned effective November 22, 2020, due to ongoing legal issues in China, although no charges have been filed against him or Legend Biotech. The Board expressed gratitude for Dr. Zhang's contributions, while the company focuses on advancing its lead product candidate, ciltacabtagene autoleucel, for multiple myeloma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
management
Rhea-AI Summary

Legend Biotech reported financial results for Q3 2020, with revenues of $11.7 million, down from $17.7 million in Q3 2019. The company posted a net loss of $66.5 million, or $0.25 per share, compared to a loss of $27.8 million, or $0.14 per share, in the prior year. R&D expenses surged to $63.7 million from $41.9 million due to increased clinical trials. Despite a strong cash position of approximately $449.4 million, the company has yet to generate revenue from product sales. Notably, cilta-cel received Breakthrough Therapy Designation in China and a BLA filing is anticipated soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags

FAQ

What is the current stock price of Legend Biotech (LEGN)?

The current stock price of Legend Biotech (LEGN) is $31.52 as of April 1, 2025.

What is the market cap of Legend Biotech (LEGN)?

The market cap of Legend Biotech (LEGN) is approximately 5.8B.

What is Legend Biotech Corp's core focus?

Legend Biotech focuses on developing innovative cell therapies, especially CAR-T immunotherapy, to treat challenging cancers like multiple myeloma.

How does Legend Biotech generate revenue?

The company generates revenue through strategic licensing and collaboration agreements, leveraging its innovative product pipeline and research advancements.

What distinguishes Legend Biotech's CAR-T therapies?

Their CAR-T therapies are designed using proprietary cellular engineering techniques to enhance immune cell targeting of malignant cells, demonstrating promising efficacy in clinical trials.

In which clinical areas does Legend Biotech operate?

Legend Biotech primarily operates in oncology, developing cell therapies for both liquid and solid tumors, with a significant focus on multiple myeloma.

What is the importance of the company’s R&D efforts?

Their global R&D facilities and teams of experts ensure a rigorous approach to clinical development, fostering innovation and maintaining high standards in therapeutic research.

How is Legend Biotech positioned in the global market?

Through strategic collaborations and robust clinical trial data, Legend Biotech has established itself as a respected and influential player in advanced cell therapy and cancer treatment.

What types of therapies does Legend Biotech develop?

The company develops both autologous and allogeneic cell therapies, with a strong focus on CAR-T cell therapy aimed at treating various forms of cancer.

How does Legend Biotech ensure the safety and quality of its therapies?

The company adheres to stringent quality control and regulatory standards, actively engaging with global regulatory bodies to ensure its therapies meet the highest safety and efficacy benchmarks.
Legend Biotech Corp

Nasdaq:LEGN

LEGN Rankings

LEGN Stock Data

5.80B
181.20M
1.33%
55.49%
7.14%
Biotechnology
Healthcare
Link
United States
Somerset